{
}
Merck KGaA has agreed to acquire US biotech firm SpringWorks Therapeutics for $3.9 billion, enhancing its cancer treatment portfolio. The deal, valued at $47 per share, is expected to positively impact Merck's earnings by 2027 and reflects a growing trend of pharmaceutical companies pursuing biotech acquisitions for innovation. This acquisition aligns with the industry's focus on specialized markets and targeted therapies, particularly in oncology, which is projected to see significant growth in the coming years.
UBS has rated MERCK KGAA as a 'Buy'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential loss of the entire capital invested, and does not replace tailored expert investment advice.
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of 180 euros, following the company's planned acquisition of Springworks, which aligns with its strategic goals. Merck shares rose 0.7% to EUR 120.60, indicating a 49.25% upside potential, despite a 13.8% decline since the start of 2025.
JPMorgan has maintained an "Overweight" rating for Merck KGaA, setting a target price of 190 euros, as customer ordering behavior normalizes post-destocking. Analyst Richard Vosser noted improvements in order quality, particularly in consumables and equipment. Merck shares rose by 0.4% to EUR 143.95, indicating a potential upside of nearly 32%.
The global digital neuro biomarkers market is projected to reach USD 2.82 billion by 2030, growing at a CAGR of 25.7% from 2025, driven by the rising prevalence of neurological disorders and advancements in technology. Key players are focusing on innovative solutions, including AI integration and wearable devices, to enhance patient monitoring and treatment. North America leads the market, accounting for 37.7% of revenue in 2024, as demand for effective diagnostic tools increases.
Priya Pandey, a biotechnology graduate, excels in creating engaging content across various industries, including healthcare and technology. Coherent Market Insights offers comprehensive market intelligence and consulting services, providing detailed reports on sectors like food and beverages and pharmaceuticals, with insights into market dynamics and competitive strategies. The latest report on the Lateral Flow Assay Market forecasts trends and growth from 2024 to 2031, analyzing consumer behavior and regulatory factors while highlighting key players and emerging opportunities.
The global clinical biomarkers market, valued at $25.02 billion in 2023, is projected to reach $47.25 billion by 2031, growing at a CAGR of 8.54%. This growth is driven by rising cancer cases and advancements in diagnostic technologies, despite challenges like high costs and reimbursement issues. Key players include Roche, Abbott, and Johnson & Johnson, with significant developments in biomarker testing for various diseases.
The global cell freezing media market is projected to exceed $387.5 million by 2033, growing at a CAGR of 9.66% from 2023. North America is expected to dominate the market due to advanced healthcare infrastructure, while Asia-Pacific is anticipated to experience the fastest growth, driven by low costs and a focus on biologics manufacturing. Key players include Thermo Fisher Scientific and Merck, with innovations in cryopreservation techniques fueling market expansion.
Merck shares are currently priced at €144.45, reflecting a decrease of €1.55 or 1.06%. UBS AG has issued a buy recommendation for the stock, indicating positive expectations for its performance in the near future.
UBS has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros after the recent quarterly figures, which showed few surprises. Despite a 1.1% drop in share price to EUR 144.90, the stock has risen 2.0% since the start of 2024, indicating potential for growth. The Q4 2024 balance sheet is anticipated on March 6, 2025.
Merck KGaA
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Merck KGaA acquires SpringWorks Therapeutics for 3.9 billion dollars
11:00 28.04.2025
ubs rates merck kgaa as buy amid investment considerations and risks
13:26 25.04.2025
ubs maintains buy rating for merck shares with target price of 180 euros
12:19 25.04.2025
JP Morgan maintains overweight rating for Merck with target price of 190 euros
09:48 17.01.2025
digital neuro biomarkers market projected to reach 2.82 billion by 2030
15:10 14.01.2025
lateral flow assay market analysis trends and growth opportunities 2024 to 2031
United States Dollar
QuidelOrtho Corporation
Hologic Inc
Thermo Fisher Scientific Inc.
QIAGEN NV
Siemens AG
Abcam plc
PerkinElmer Inc
Danaher Corporation
Eiken Chemical Co., Ltd.
Becton, Dickinson and Company
Merck KGaA
Bio-Rad Laboratories Inc
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Biomerieux SA
FRA
ARG
NZL
CAN
TUR
SAU
ARE
USA
RUS
IND
AUS
ESP
GBR
SGP
BRA
IRN
CHN
DEU
MEX
ITA
JPN
Priya Pandey
Show more
09:06 10.01.2025
global clinical biomarkers market projected to reach 47 billion by 2031
Eurofins Scientific S.E. A
PerkinElmer Inc
Johnson & Johnson Services Inc.
Bio-Rad Laboratories, Inc.
Qiagen N.V.
Merck KGaA
Thermo Fisher Scientific Inc.
General Electric Co
Siemens Healthineers AG
Agilent Technologies, Inc.
F. Hoffmann-La Roche Ltd.
USA
Show more
08:45 16.12.2024
global cell freezing media market poised for significant growth by 2033
United States Dollar
Hemacare Company
Capricorn Scientific GmbH
Sartorius Aktiengesellschaft
Cellular Applications, Inc.
PromoCell GmbH
Himedia Laboratories Ltd.
Merck KGaA
BioLife Solutions, Inc.
Mediatech, Inc.
Thermo Fisher Scientific Inc.
Nippon Genetics
AMSBIO
USA
QAT
DEU
ITA
FRA
MEX
ARG
AUS
ZAF
IND
SAU
RUS
JPN
KOR
GBR
BRA
CAN
ARE
ESP
CHN
Show more
04:05 19.11.2024
Merck shares analyzed with buy recommendation from UBS AG
11:47 15.11.2024
ubs maintains buy rating for merck with target price of 190 euros
11:37 15.11.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: